Palvella Therapeutics (NASDAQ:PVLA) Research Coverage Started at Scotiabank

Scotiabank initiated coverage on shares of Palvella Therapeutics (NASDAQ:PVLA) in a research note issued to investors on Friday morning, Marketbeat Ratings reports. The firm issued a sector outperform rating and a $50.00 price objective on the stock.

Several other equities research analysts have also weighed in on the stock. Cantor Fitzgerald assumed coverage on shares of Palvella Therapeutics in a research note on Wednesday, December 18th. They set an “overweight” rating on the stock. HC Wainwright restated a “buy” rating and issued a $38.00 target price on shares of Palvella Therapeutics in a research report on Tuesday, February 11th. Canaccord Genuity Group restated a “buy” rating and issued a $39.00 target price on shares of Palvella Therapeutics in a research report on Wednesday, February 26th. Finally, TD Cowen assumed coverage on shares of Palvella Therapeutics in a research report on Wednesday, February 5th. They issued a “buy” rating and a $44.00 target price for the company. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $42.75.

Palvella Therapeutics Trading Up 2.5 %

Shares of Palvella Therapeutics stock opened at $24.55 on Friday. The firm has a market cap of $275.48 million, a price-to-earnings ratio of -2.03 and a beta of 0.54. Palvella Therapeutics has a 1 year low of $6.20 and a 1 year high of $25.22. The firm has a 50-day moving average of $15.94.

Insider Activity

In related news, Director George M. Jenkins acquired 4,000 shares of the firm’s stock in a transaction dated Wednesday, December 18th. The stock was acquired at an average cost of $12.93 per share, for a total transaction of $51,720.00. Following the completion of the acquisition, the director now directly owns 180,671 shares of the company’s stock, valued at approximately $2,336,076.03. The trade was a 2.26 % increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 6.39% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Toronto Dominion Bank bought a new position in shares of Palvella Therapeutics in the fourth quarter valued at approximately $159,000. Frazier Life Sciences Management L.P. bought a new position in shares of Palvella Therapeutics in the fourth quarter valued at approximately $7,847,000. Suvretta Capital Management LLC bought a new position in shares of Palvella Therapeutics in the fourth quarter valued at approximately $8,574,000. DAFNA Capital Management LLC bought a new position in shares of Palvella Therapeutics in the fourth quarter valued at approximately $857,000. Finally, Cresset Asset Management LLC bought a new position in shares of Palvella Therapeutics in the fourth quarter valued at approximately $251,000. 40.11% of the stock is currently owned by institutional investors.

About Palvella Therapeutics

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.